Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - December 12, 2025 290 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the DESTINY-Breast05 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Returning to Dental Care August 24, 2020 FDA Approves Tebentafusp-tebn for Unresectable or Metastatic Uveal Melanoma February 7, 2022 Invasive Lobular Carcinoma Is Invisible On Mammograms, Isn’t A Lump April 4, 2019 FDA Approves Pembrolizumab for Cutaneous Squamous Cell Carcinoma June 26, 2020 Load more HOT NEWS Reunión anual de la American Society of Clinical Oncology de 2021:... Breast Cancer Survivor Earned Yoga Instructor Certification During Chemo. Now She... This Company Is Turning Scrap Wood Into 10,000+ Guitars For Sick... EMA Starts Review of Rucaparib
